{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T10:53:47Z","timestamp":1793962427571,"version":"4.8.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100018937","name":"Bavarian Nordic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015340","name":"Bayer Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015340","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.eururo.2015.06.039","type":"journal-article","created":{"date-parts":[[2015,7,5]],"date-time":"2015-07-05T13:38:46Z","timestamp":1436103526000},"page":"850-858","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options"],"prefix":"10.1016","volume":"68","author":[{"given":"Benjamin A.","family":"Gartrell","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Coleman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Efstathiou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guru","family":"Sonpavde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fred","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2015.06.039_bib0255","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3322\/caac.21208","article-title":"Cancer statistics, 2014","volume":"64","author":"Siegel","year":"2014","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2015.06.039_bib0260","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1002\/cncr.11635","article-title":"Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base","volume":"98","author":"Miller","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2015.06.039_bib0265","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0270","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.06.039_bib0275","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2015.06.039_bib0280","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1093\/annonc\/mdi122","article-title":"The significance of skeletal-related events for the health-related quality of life of patients with metastatic prostate cancer","volume":"16","author":"Weinfurt","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0285","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1038\/pcan.2011.7","article-title":"Mortality following bone metastasis and skeletal-related events among men with prostate cancer: a population-based analysis of US Medicare beneficiaries, 1999-2006","volume":"14","author":"Sathiakumar","year":"2011","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.eururo.2015.06.039_bib0290","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.eururo.2012.05.007","article-title":"Prostate-specific antigen kinetics and outcomes in patients with bone metastases from castration-resistant prostate cancer treated with or without zoledronic acid","volume":"65","author":"Saad","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0295","doi-asserted-by":"crossref","first-page":"849","DOI":"10.3109\/07357907.2010.483508","article-title":"Disease progression increases the risk of skeletal-related events in patients with bone metastases from castration-resistant prostate cancer, lung cancer, or other solid tumors","volume":"28","author":"Tchekmedyian","year":"2010","journal-title":"Cancer Invest"},{"key":"10.1016\/j.eururo.2015.06.039_bib0300","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/jnci\/dji002","article-title":"Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors","volume":"97","author":"Brown","year":"2005","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2015.06.039_bib0305","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.eururo.2014.10.001","article-title":"Bone-related parameters are the main prognostic factors for overall survival in men with bone metastases from castration-resistant prostate cancer","volume":"68","author":"Fizazi","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0310","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2002.20.3.850","article-title":"Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status","volume":"20","author":"Costa","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0315","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1046\/j.1464-410x.2001.00105.x","article-title":"The serum level of the amino-terminal propeptide of type I procollagen is a sensitive marker for prostate cancer metastasis to bone","volume":"87","author":"Koizumi","year":"2001","journal-title":"BJU Int"},{"key":"10.1016\/j.eururo.2015.06.039_bib0320","doi-asserted-by":"crossref","first-page":"3361","DOI":"10.1158\/1078-0432.CCR-06-0269","article-title":"Markers of bone metabolism and survival in men with hormone-refractory metastatic prostate cancer","volume":"12","author":"Cook","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2015.06.039_bib0325","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1093\/annonc\/mdq037","article-title":"Urinary N-telopeptide (uNTx) is an independent prognostic factor for overall survival in patients with bone metastases from castration-resistant prostate cancer","volume":"21","author":"Rajpar","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0330","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2015.06.039_bib0335","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1126\/science.289.5484.1504","article-title":"Bone resorption by osteoclasts","volume":"289","author":"Teitelbaum","year":"2000","journal-title":"Science"},{"key":"10.1016\/j.eururo.2015.06.039_bib0340","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.eururo.2015.06.039_bib0345","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/16852","article-title":"OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis","volume":"397","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2015.06.039_bib0350","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.eururo.2015.06.039_bib0355","first-page":"98","article-title":"The distribution of secondary growths in cancer of the breast","volume":"8","author":"Paget","year":"1989","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.eururo.2015.06.039_bib0360","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.eururo.2015.06.039_bib0365","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI43414","article-title":"Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow","volume":"121","author":"Shiozawa","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eururo.2015.06.039_bib0370","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.1002\/1097-0142(20000615)88:12+<2892::AID-CNCR2>3.0.CO;2-Y","article-title":"Molecular mechanisms of osteolytic bone metastases","volume":"88","author":"Guise","year":"2000","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2015.06.039_bib0375","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1002\/jcb.10662","article-title":"Prostate cancer bone metastases promote both osteolytic and osteoblastic activity","volume":"91","author":"Keller","year":"2004","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.eururo.2015.06.039_bib0380","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2015.06.039_bib0385","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.06.039_bib0390","first-page":"252","article-title":"Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice","volume":"44","author":"Henriksen","year":"2003","journal-title":"J Nucl Med"},{"key":"10.1016\/j.eururo.2015.06.039_bib0395","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/266653a0","article-title":"High-LET radiations induce a large proportion of non-rejoining DNA breaks","volume":"266","author":"Ritter","year":"1977","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2015.06.039_bib0400","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2015.06.039_bib0405","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0410","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1016\/j.eururo.2013.05.025","article-title":"Management of biochemical recurrence after primary treatment of prostate cancer: a systematic review of the literature","volume":"64","author":"Punnen","year":"2013","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0415","doi-asserted-by":"crossref","first-page":"2918","DOI":"10.1200\/JCO.2005.01.529","article-title":"Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer","volume":"23","author":"Smith","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0420","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/j.eururo.2014.02.014","article-title":"Prevention of bone metastases in patients with high-risk nonmetastatic prostate cancer treated with zoledronic acid: efficacy and safety results of the Zometa European Study (ZEUS)","volume":"67","author":"Wirth","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0425","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2015.06.039_bib0430","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"Suppl 6","key":"10.1016\/j.eururo.2015.06.039_bib0435","article-title":"Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract 19]","volume":"31.","author":"Nilsson","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0440","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ejca.2011.12.023","article-title":"A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer","volume":"48","author":"Nilsson","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.eururo.2015.06.039_bib0445","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"issue":"Suppl","key":"10.1016\/j.eururo.2015.06.039_bib0450","article-title":"Impact of concomitant bone-targeted therapies (BTT) on outcomes in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) without prior chemotherapy (ctx) treated with abiraterone acetate (AA) or prednisone (P) [abstract 5037]","volume":"31","author":"Saad","year":"2013","journal-title":"J Clin Oncol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2015.06.039_bib0455","volume":"31","author":"James","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0460","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1359\/jbmr.090810","article-title":"Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure","volume":"25","author":"Body","year":"2010","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eururo.2015.06.039_bib0465","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.juro.2009.04.023","article-title":"Denosumab treatment of prostate cancer with bone metastases and increased urine N-telopeptide levels after therapy with intravenous bisphosphonates: results of a randomized phase II trial","volume":"182","author":"Fizazi","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0470","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1200\/JCO.2008.19.2146","article-title":"Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates","volume":"27","author":"Fizazi","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0475","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1200\/JCO.2013.51.6500","article-title":"Randomized controlled trial of early zoledronic acid in men with castration-sensitive prostate cancer and bone metastases: results of CALGB 90202 (Alliance)","volume":"32","author":"Smith","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0480","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2015.06.039_bib0485","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"Suppl 9","key":"10.1016\/j.eururo.2015.06.039_bib0490","article-title":"Safety of cytotoxic chemotherapy following radium-223 chloride (RA-223) therapy in the phase 3 ALSYMPCA study in patients with castration-resistant prostate cancer (CRPC) with bone metastases [abstract 936P]","volume":"23","author":"Sartor","year":"2012","journal-title":"Ann Oncol"},{"issue":"Suppl","key":"10.1016\/j.eururo.2015.06.039_bib0495","article-title":"Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): a phase I Prostate Cancer Clinical Trials Consortium study [abstract 5021]","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"10.1016\/j.eururo.2015.06.039_bib0500","article-title":"Safety of radium-223 dichloride (Ra) with docetaxel (D) in patients (pts) with bone metastases (mets) from castration-resistant prostate cancer (CRPC): a phase 1\/2a clinical trial [abstract 765PD]","volume":"25","author":"Morris","year":"2014","journal-title":"Ann Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815005424?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815005424?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,27]],"date-time":"2022-06-27T11:36:01Z","timestamp":1656329761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283815005424"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":50,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2015,11]]}},"alternative-id":["S0302283815005424"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2015.06.039","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2015.06.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}